Lataa...
JAK1 Genomic Alteration Associated With Exceptional Response to Siltuximab in Cutaneous Castleman Disease
IMPORTANCE: Castleman disease (CD) is an ultrarare, interleukin-6 (IL-6)–driven lymphoproliferative disorder whose underlying molecular alterations are unknown. Siltuximab (anti–IL-6 antibody) is approved for treatment of this disease. To our knowledge, genomic sequencing of CD has not been reported...
Tallennettuna:
| Julkaisussa: | JAMA Dermatol |
|---|---|
| Päätekijät: | , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Medical Association
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5470416/ https://ncbi.nlm.nih.gov/pubmed/28241173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2016.5554 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|